ANDAs For Proteins Regulated As Drugs Could Lead To Lawsuits - Genzyme
Executive Summary
FDA could face legal challenges if it accepts abbreviated NDAs for products regulated as drugs that possess characteristics similar to biologics, Genzyme Senior VP-Government Relations Lisa Raines argued Oct. 3 at the Regulatory Affairs Professionals Society conference in Washington, D.C.
You may also be interested in...
FDA Intercenter Agreements Would Be Rewritten Under Greenwood/Eshoo Bill
FDA would be directed to review its intercenter product jurisdiction agreements to ensure that reviews are assigned based on "the primary mode of action" under a bill sponsored by Reps. Jim Greenwood (R-Penn.) and Anna Eshoo (D-Calif.)
FDA Intercenter Agreements Would Be Rewritten Under Greenwood/Eshoo Bill
FDA would be directed to review its intercenter product jurisdiction agreements to ensure that reviews are assigned based on "the primary mode of action" under a bill sponsored by Reps. Jim Greenwood (R-Penn.) and Anna Eshoo (D-Calif.)
Generic Biologics Bill Could Be Follow Up To Medicare Rx Benefit - Haddad
Legislation permitting generic versions of biological products will be a natural outgrowth of the addition of prescription drug coverage to Medicare, Hadco Biotechnology CEO William Haddad predicted during a Food & Drug Law Institute conference Dec. 11 in Washington, D.C.